Literature DB >> 16475272

Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers.

Wah Yau Wong1, Carl I DeLuca, Baomin Tian, Iain Wilson, Sharon Molund, Nalini Warriar, Manjapra V Govindan, Donald Segal, Heman Chao.   

Abstract

Jack bean urease catalyzes the decomposition of urea into ammonia, which in turn increases the pH of the surrounding medium. Based on these two properties, we have investigated the antitumor effects of urease in vitro and in vivo on human lung and breast cancer cell lines either by the enzyme itself or in combination with other chemotherapeutic drugs. First, through the generation of toxic ammonia, urease exerted direct cytotoxicity on A549 and MDA-MB-231 tumor cells with LC50 of 0.22 and 0.45 U/ml, respectively. The cytotoxic effects could effectively be blocked using the reversible urease inhibitor acetohydroxamic acid. Complete protection was observed at dose > or = 2 mM. In addition, nude mouse xenograft models demonstrated that intratumoral urease injections (1 - 10 U/dose) inhibited A549 and MCF-7 tumor growth in vivo. Second, when combined with weak-base anticancer drugs, urease provided indirect antitumor effects via pH augmentation. Alkalinization of extracellular pH by urease (2 U/ml) and urea (> or = 2 mM) was found to enhance the antitumor efficacy of doxorubicin (50 microM) and vinblastine (100 microM) significantly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16475272

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  7 in total

1.  Extracellular urease from Arthrobacter creatinolyticus MTCC 5604: scale up, purification and its cytotoxic effect thereof.

Authors:  Ramesh Rajendran; Ajitha Pandi; Aparna Ramchary; Hemalatha Thiagarajan; Jithendra Panneerselvam; Ayyadurai Niraikulam; Gowthaman Marichetti Kuppuswami; Kamini Numbi Ramudu
Journal:  Mol Biol Rep       Date:  2018-10-29       Impact factor: 2.316

2.  A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC.

Authors:  Sarina Piha-Paul; George Simon; Chandra P Belani; Heman Chao; Kim Gaspar; Brenda Lee; Afshin Dowlati
Journal:  JTO Clin Res Rep       Date:  2022-09-16

Review 3.  Immunotherapy on acid: opportunities and challenges.

Authors:  Sultan Damgaci; Pedro M Enriquez-Navas; Shari Pilon-Thomas; Albert Guvenis; Robert J Gillies; Arig Ibrahim-Hashim
Journal:  Eur J Clin Nutr       Date:  2020-08       Impact factor: 4.016

Review 4.  Hypoxia and acidosis: immune suppressors and therapeutic targets.

Authors:  Sultan Damgaci; Arig Ibrahim-Hashim; Pedro M Enriquez-Navas; Shari Pilon-Thomas; Albert Guvenis; Robert J Gillies
Journal:  Immunology       Date:  2018-03-30       Impact factor: 7.397

5.  Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2.

Authors:  Baomin Tian; Wah Yau Wong; Marni D Uger; Pawel Wisniewski; Heman Chao
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

Review 6.  What do cellular responses to acidity tell us about cancer?

Authors:  Wiktoria Blaszczak; Pawel Swietach
Journal:  Cancer Metastasis Rev       Date:  2021-11-30       Impact factor: 9.264

7.  Anticancer Activity of Urease Mimetic Cobalt (III) Complexes on A549-Lung Cancer Cells: Targeting the Acidic Microenvironment.

Authors:  Bhawna Uprety; Rahul Chandran; Charmaine Arderne; Heidi Abrahamse
Journal:  Pharmaceutics       Date:  2022-01-17       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.